Description.
We are seeking bacterial candidates (either mixed or single strains) that, when administered into the nasal cavity, could confer benefits for immunity, particularly in conditions such as allergies or colds. This entails enhancing the immune system's ability to combat allergens or viral agents.
Background.
The topic of respiratory (nasal or pulmonary) microbiota and its relationship with respiratory allergy or cold disorders (viral infectious) is emerging.
Key Success Criteria.
Must-have Requirements.
- Data (clinical or/and preclinical data) supporting the expected activity/mode of action: superiority in fighting allergens or viruses via interaction of nasal microbiota & immune system.
- Complete strain characterization (e.g. genomic sequence – stability).
Have a question or simply want to know more?
Any question or adverse reaction related to our products must be addressed via www.sanofi.com.
